Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01124708 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 study, sponsored by Targacept.
- Completed
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
NCT01124708 is a Phase 2 study that has completed, run by Targacept. The registered enrollment target is 134 participants.
The verdict
NCT01124708, a Phase 2 study, has completed, sponsored by Targacept.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
Study Summary
ADHD has been associated with persistent deficits in the efficient allocation of attention and supports the notion that regulation of the cholinergic system may improve these cognitive deficits in ADHD. It has been suggested that the effects of nicotine are most pronounced on tasks that demand effortful processing (Rusted and Warburton 1994). In addition, a recent theory proposes that the cholinergic system allocates additional attentional resources during tasks that are demanding (i.e. sustained attention, set shifting, etc; Sarter and Bruno 1997). Thus it may be that in ADHD, cholinergic systems are under-responsive or under-developed and thus stimulation of nicotinic receptors via nicotinic agents may result in improved cognitive performance particularly on tests requiring effortful processing.
Interventions
- DRUG Placebo
- DRUG TC-5619-238
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01124708
The ClinicalTrials.gov registry entry for NCT01124708 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Targacept, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01124708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01124708 about?
NCT01124708 is a clinical study titled "Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)". ADHD has been associated with persistent deficits in the efficient allocation of attention and supports the notion that regulation of the cholinergic system may improve these cognitive deficits in ADHD. It has been suggested that the effects of nicotine are most pronounced on tasks that demand effor...
What is the current status of trial NCT01124708?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2010-05. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01124708?
The interventions under investigation include: Placebo (DRUG), TC-5619-238 (DRUG).
Who is sponsoring clinical trial NCT01124708?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.